Once-Daily Dosing of Lamivudine and Abacavir for Pediatric Patients
April 20, 2015
The U.S. Food and Drug Administration has approved once-daily dosing recommendations for lamivudine and abacavir for HIV-infected children. Previously, these NRTIs were approved only for twice-daily dosing in children. The dosing revisions apply to both the oral solution and the tablet formulations of these drugs.
Lamivudine (children aged 3 months to 16 years)
- 8 mg/kg QD or 4 mg/kg BID; maximum 300 mg per day
- Wt 14 to <20 kg: 150 mg QD or 75 mg BID
- Wt ≥20 to <25 kg: 225 mg QD, or 75 mg QAM + 150 mg QPM
- Wt ≥25 kg: 300 mg QD or 150 mg BID (adult dosage)
Abacavir (children aged 3 months to 16 years)
- 16 mg/kg QD or 8 mg/kg BID; maximum 600 mg per day
- Wt 14 to <20 kg: 300 mg QD or 150 mg BID
- Wt ≥20 to <25 kg: 450 mg QD, or 150 mg QAM + 300 mg QPM
- Wt ≥25 kg: 600 mg QD or 300 mg BID (adult dosage)
The updated prescribing information should soon be available on [email protected].
Susa Coffey is medical editor of the NCRC. She is a Professor of Medicine at UCSF in the Division of HIV, Infectious Diseases and Global Medicine and a longtime clinician and educator in the HIV at San Francisco General Hospital clinic (“Ward 86”). She also is medical editor of HIV InSite.